Clinical Trial Update: Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in patients with NPM1-mutated acute myeloi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• All-trans Retinoic Acid (all-trans retinoic acid)
• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AML | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION